Global development of innovative drugs for the treatment of chronic liver diseases, are you ready?
- Breakthroughs & Innovations: Metabolic Associated Fatty Liver Disease (MAFLD)
- Breakthrough & Innovation: Alcoholic Liver Disease (ALD)
- Breakthrough & Innovation: Drug-Induced Liver Injury (DILI)
- Global blockbuster liver disease drugs expected to be marketed in the following 3 years
- Pipeline layout of top 10 chronic liver disease enterprises in China
- An innovative biotech roadshow
Event details
|
DATE Tuesday, Apr 29, 2025 VENUE Online Webex / Zoom TIME 8:00 – 9:00 Berlin time (CET) 14:00 – 15:00 Beijing time (GMT+8) RSVP This is a complimentary event VIP tickets priority for Lingmed current clients Please RSVP by Apr 29, 2025 |
PRESENTERS Lingling Cao, CEO & Founder REGISTER +86 21 5386 3003 info@lingmed.cn |
Agenda
| CET 8:00 - 8:30 | Global development of innovative drugs for the treatment of chronic liver diseases |
by Guest speaker (Chinese) |
| CET 8:30 - 8:35 | Linkedbio services & projects introduction | by Lingling Cao (English) |
| CET 8:35 - 8:55 | An innovative biotech roadshow | by Guest speaker (English) |
| CET 8:55 – 9:00 | Q&A | (English & Chinese) |
Presenters
 |
Lingling Cao CEO & Founder Lingling has more than a decade of experience in the healthcare industry, especially in deal-making. She founded Lingmed, which aims to support BD professionals to make better decisions with intelligence databases and EU-China cross-border deals. Prior to her venture at Lingmed, she was a senior BD manager for Eli Lilly in Shanghai and a consultant for McKinsey in Germany |